New Immune Checkpoint Found as Neutrophils Sabotage Cancer-Fighting T Cells
Scientists identify CD300ld as a key mechanism by which tumor-infiltrating neutrophils silence CD8+ T cells, opening a new immunotherapy target.
Summary
Researchers have uncovered how certain immune cells called neutrophils — when hijacked by tumors — directly shut down the body's cancer-killing T cells. The culprit is a protein called CD300ld on these rogue neutrophils, which grabs onto a molecule called phosphatidylserine on CD8+ T cells, essentially putting the brakes on the immune attack. When scientists blocked this interaction using antibodies in mice, tumors shrank — and the effect was even stronger when combined with existing anti-PD1 immunotherapy. This discovery reveals a previously unknown immune checkpoint that cancer exploits and suggests new ways to help patients whose tumors resist current immunotherapy drugs.
Detailed Summary
Cancer's ability to evade the immune system is one of the biggest challenges in oncology. Even with powerful immunotherapies like anti-PD1 checkpoint inhibitors, many patients do not respond. Understanding why tumors stay protected despite treatment is critical for developing better therapies.
This study focuses on a class of immune cells called polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) — essentially neutrophils that tumors reprogram into immune suppressors. These cells directly contact CD8+ cytotoxic T cells and prevent them from killing tumor cells, but the precise molecular handshake enabling this suppression was unclear. Building on prior work implicating CD300ld in PMN-MDSC recruitment, this team now reveals what CD300ld actually does once these cells are inside the tumor.
The key finding is that CD300ld binds to phosphatidylserine (PS), a lipid normally found on the inner membrane of healthy cells but exposed on the surface of stressed or suppressed T cells. This physical contact disables CD8+ T cells. When researchers engineered mice carrying a CD300ld variant incapable of binding PS, immunosuppressive activity dropped significantly, and tumor control improved.
Critically, neutralizing antibodies that block the CD300ld-PS interaction showed therapeutic efficacy in mouse tumor models, and the effect was amplified when combined with anti-PD1 therapy. This synergy suggests CD300ld represents a complementary and non-redundant checkpoint — meaning it operates through a pathway distinct from the PD-1/PD-L1 axis.
The implications for oncology are significant. A substantial fraction of tumors are enriched with PMN-MDSCs and are resistant to current checkpoint blockade. CD300ld-targeting antibodies could extend immunotherapy benefit to these patients. Caveats include preclinical-only data and abstract-limited reporting, but the findings are published in Nature Cancer, lending strong credibility.
Key Findings
- CD300ld on tumor-infiltrating neutrophils suppresses CD8+ T cells by binding phosphatidylserine exposed on their surface.
- Mutant mice with PS-binding-deficient CD300ld showed significantly reduced tumor immune evasion.
- Neutralizing antibodies blocking CD300ld-PS interaction demonstrated anti-tumor efficacy in established mouse tumor models.
- Combining CD300ld blockade with anti-PD1 therapy produced synergistic anti-tumor effects.
- CD300ld-PS defines a novel, targetable immune checkpoint distinct from the PD-1/PD-L1 pathway.
Methodology
The study used mouse tumor models with engineered CD300ld point mutants lacking phosphatidylserine-binding capacity to dissect the mechanism. Neutralizing antibody interventions were tested alone and in combination with anti-PD1 therapy. Full methodology details are unavailable as access is limited to the abstract.
Study Limitations
This summary is based on the abstract only; full methodology, sample sizes, and data depth could not be assessed. All efficacy data are from mouse models and require validation in human clinical trials before conclusions about patient benefit can be drawn. The specificity of CD300ld-PS interactions across different tumor types and patient populations remains to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.